Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243874 | 0.88 | KRAS (0.79) | KRAS | |
| SCHEMBL21243889 | 0.88 | KRAS (0.79) | KRAS | |
| SCHEMBL21243920 | 0.88 | KRAS (0.79) | KRAS | |
| SCHEMBL21263730 | 0.87 | KRAS (0.63) | KRAS | |
| SCHEMBL21243941 | 0.85 | KRAS (0.47) | KRAS | |
| SCHEMBL21243878 | 0.79 | KRAS (0.72) | KRAS | |
| SCHEMBL21733653 | 0.78 | KRAS (0.55) | KRAS | |
| SCHEMBL21722262 | 0.78 | KRAS (0.55) | KRAS | |
| SCHEMBL21722237 | 0.78 | KRAS (0.55) | KRAS | |
| SCHEMBL30178113 | 0.78 | KRAS (0.55) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749665-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | TOP2A, TOP1, TOP2B | KRAS 149/4885 |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | TOP2A, TOP1, TOP2B | KRAS 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.